Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects With Relapsed and/or Refractory Diffuse Large B Cell Lymphoma

NCT04792489 is registered in ClinicalTrials.gov with Miltenyi Biomedicine GmbH as lead sponsor.

NCT NCT04792489
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04792489 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects With Relapsed and/or Refractory Diffuse Large B Cell Lymphoma
Lead sponsor
Miltenyi Biomedicine GmbH
Phase
Phase 2
Overall status
Recruiting
Start date
May 25, 2021
Completion date
December 31, 2028
Enrollment
315 (estimated)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

central nervous system lymphoma, high grade b-cell lymphoma (hgbcl), mantle cell lymphoma (mcl), primary mediastinal b-cell lymphoma (pmbcl), refractory diffuse large b cell lymphoma (dlbcl), relapsed diffuse large b cell lymphoma, richter transformation, transformed lymphoma, transplant-ineligible 2nd line dlbcl